GNFT (GNFT) Stock Analysis

GNFT (GNFT) Healthcare & Pipeline Overview

Genfit S.A. is a biopharmaceutical innovator specializing in drug candidates and diagnostic solutions for metabolic and liver diseases, with a strong focus on clinical development and partnerships to enhance patient care.

What Is the Investment Thesis for GNFT?

Genfit S.A. is positioned for growth through its diverse pipeline of drug candidates and diagnostic solutions targeting significant unmet medical needs in the liver disease space. The company's lead product, Elafibranor, is in Phase 3 trials, which, if successful, could lead to substantial market entry and revenue generation. Additionally, the development of NIS4 technology for diagnosing NASH and fibrosis represents a strategic advantage, as the global NASH market is projected to grow significantly, driven by increasing prevalence rates. Genfit's partnerships with Labcorp and Genoscience Pharma further enhance its capabilities and market presence, providing additional revenue streams and collaborative opportunities. However, the company faces risks, including the challenges of clinical trial outcomes and market competition, which could impact its growth trajectory. Overall, Genfit's focus on innovative therapies and diagnostics positions it well within the expanding biotechnology sector.

Based on FMP financials and quantitative analysis

GNFT Key Highlights

Market Cap of $446M reflects the company's current valuation in the biotechnology sector.

• Profit Margin of -127.4% indicates ongoing investment in R&D, typical for companies in clinical development stages.
• Gross Margin of 26.0% demonstrates the company's ability to manage costs associated with its product development.
• Beta of 0.87 suggests lower volatility compared to the broader market, which may appeal to risk-averse investors.
• No dividend yield as the company reinvests earnings into research and development to drive future growth.

Who Are GNFT's Competitors?

GNFT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are GNFT's Key Strengths?

Innovative pipeline targeting significant unmet medical needs in liver diseases.

• Strong partnerships with established healthcare organizations.
• Experienced management team with a proven track record in biotechnology.

What Are GNFT's Weaknesses?

High reliance on successful clinical trial outcomes for revenue generation.

• Negative profit margins reflecting ongoing investment in R&D.
• Limited market presence compared to larger pharmaceutical companies.

What Could Drive GNFT Stock Higher?

GNFT catalyst: Results from Phase 3 clinical trials for Elafibranor are anticipated, which could lead to market approval and revenue generation.

• Development of NIS4 technology for NASH diagnosis continues, with increasing demand for effective diagnostic tools.
• Potential partnership announcements for GNS561 could enhance development and commercialization efforts.
• Clinical trials for Nitazoxanide are progressing, with updates expected in the near future.
• Expansion of market presence through strategic collaborations and licensing agreements.

What Are the Key Risks for GNFT?

Financial-distress signal — its Altman Z-Score of -0.08 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Rich valuation — a P/E of 257.07 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
• Clinical trial failures could delay or prevent product commercialization, impacting revenue projections.
• Regulatory challenges may arise during the approval process for new drugs and diagnostics.
• Competition from larger pharmaceutical companies could hinder market penetration for Genfit's products.
• Market volatility may affect funding opportunities and investor sentiment.

What Are the Growth Opportunities for GNFT?

• Growth opportunity 1: The global NASH market is projected to grow at a CAGR of over 30% through 2028, driven by rising obesity rates and increased awareness of liver health. Genfit's NIS4 technology for diagnosing NASH could capture significant market share as healthcare providers seek effective diagnostic solutions.
• Growth opportunity 2: Elafibranor's Phase 3 trial outcomes could lead to market approval, opening new revenue streams. The primary biliary cholangitis market is expected to grow substantially, providing Genfit with a competitive advantage if Elafibranor is successfully commercialized.
• Growth opportunity 3: The collaboration with Labcorp for the commercialization of NASHnext positions Genfit to leverage Labcorp's extensive distribution network, enhancing market access and accelerating revenue generation from diagnostic solutions.
• Growth opportunity 4: The development of GNS561 for cholangiocarcinoma is timely as the incidence of this cancer type is rising. With limited treatment options available, successful clinical trials could position Genfit as a leader in this niche market.
• Growth opportunity 5: The increasing focus on personalized medicine provides Genfit with opportunities to tailor its diagnostic solutions and treatments, enhancing patient outcomes and potentially leading to higher market adoption rates.

What Threats Does GNFT Face?

• Intense competition from established and emerging biotechnology firms.
• Regulatory challenges in drug approval processes.
• Market volatility affecting investment and funding opportunities.

What Are GNFT's Competitive Advantages?

• Strong pipeline of innovative drug candidates with potential for market differentiation.
• Established partnerships with leading healthcare organizations enhance credibility and market reach.
• Focus on niche therapeutic areas with high unmet medical needs provides a competitive edge.
• Proprietary diagnostic technologies like NIS4 position Genfit as a leader in liver disease diagnostics.
• Experienced management team with a track record in biotechnology and pharmaceuticals.

What Does GNFT Do?

Founded in 1999 and headquartered in Loos, France, Genfit S.A. is a biopharmaceutical company dedicated to discovering and developing drug candidates and diagnostic solutions targeting metabolic and liver-related diseases. The company has made significant strides in the biotechnology sector, particularly with its lead product, Elafibranor, which is currently in Phase 3 clinical trials aimed at treating primary biliary cholangitis, a chronic liver disease. In addition to Elafibranor, Genfit is advancing its NIS4 technology, a diagnostic tool for nonalcoholic steatohepatitis (NASH) and liver fibrosis, which represents a critical area of unmet medical need. The company is also developing GNS561, an investigational treatment for cholangiocarcinoma (CCA), currently in Phase 1b/2 trials, and Nitazoxanide, which is in Phase 1 trials for acute-on-chronic liver failure. Genfit has established licensing agreements with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test, and with Genoscience Pharma for the development of GNS561. These strategic partnerships enhance Genfit's market position and broaden its reach in the healthcare landscape. With a dedicated workforce of 180 employees, Genfit continues to focus on innovation and research to address the growing challenges associated with liver diseases and metabolic disorders.

What Products and Services Does GNFT Offer?

• Develops innovative drug candidates for metabolic and liver diseases.
• Conducts clinical trials to evaluate the safety and efficacy of its products.
• Offers diagnostic solutions like NIS4 for liver disease assessment.
• Engages in strategic partnerships to enhance product development and market access.
• Focuses on addressing unmet medical needs in the healthcare sector.
• Operates primarily in the biotechnology industry with a strong emphasis on research and development.

How Does GNFT Make Money?

• Generates revenue through the commercialization of drug candidates upon successful clinical trial outcomes.
• Licenses diagnostic technologies to healthcare providers and laboratories.
• Collaborates with other pharmaceutical companies to co-develop and market treatments.
• Invests heavily in R&D to innovate and expand its product pipeline.
• Utilizes partnerships to leverage existing market channels for faster product access.

What Industry Does GNFT Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in drug development and increasing investment in healthcare innovation. The global biotechnology market is projected to reach approximately $2.4 trillion by 2028, with significant contributions from companies focusing on metabolic and liver diseases. Genfit S.A. operates within this dynamic landscape, where competition is fierce, particularly in the areas of NASH and liver disease treatments. As the demand for effective therapies continues to rise, Genfit's focus on innovative solutions positions it favorably among its peers.

Who Are GNFT's Key Customers?

• Healthcare providers seeking innovative treatments for liver diseases.
• Patients diagnosed with metabolic and liver-related conditions.
• Laboratories and diagnostic centers utilizing Genfit's diagnostic solutions.
• Pharmaceutical companies interested in collaboration for drug development.
• Investors looking for opportunities in the biotechnology sector.

GNFT Financial Trajectory

GNFT (GNFT) reported $35.5M in revenue for Jun 2025, reflecting 502.3% growth compared to the prior quarter. The company recorded a net loss of $10.0M, with diluted EPS of $-0.20. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare.

Company Profile

GNFT operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Loos, FR. The company is led by CEO M. Pascal Prigent. GNFT has traded publicly since 2019.

How GNFT Is Valued

GNFT carries a market capitalization of $446M, placing it in the small-cap category.

Return on assets is -54.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.00 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -16.3%, the inverse of the P/E and a quick read on earnings relative to price.

GNFT's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.08 places it in the distress zone, a signal of elevated financial risk.

GNFT has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 4.7% above estimates on average.

Wall Street analysts project GNFT revenue of about $47.4M for fiscal 2026, with EPS near $-0.40. The estimate reflects 4 contributing analysts.

GNFT Financials

GNFT Latest News

What Investors Ask About GNFT (GNFT) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources